BiPER THERAPEUTICS
- Biotech or pharma, therapeutic R&D
First-In-Class oral selective BiP inhibitors to treat cancers. BPR001-615 is a clinical candidate at 6 months from the clinic to treat relapsing / refractory cancer patients with primary focus on gastro-intestinal cancers. BPR001615 demonstrated tumor regression and outperform 1st line chemotherapy standard of care in monotherapy. By inhibiting BiP BPR001-615 pushes cancer cells to burn out. BiP is a key protein controlling tumor survival and resistance highly overexpressed in more than 50% cancer patients’ tumors and plasma making it a non-invasive biomarker to select and treat patients with our selective BiP inhibitors
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}